On February 13, 2019 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on using the body’s immune system to fight cancer, reported that Dr. Amit Kumar, its President and CEO, will be presenting on a panel discussion at Moffitt Cancer Center’s 13th Annual Business of Biotech Conference being held on February 22, 2019 (Press release, Anixa Biosciences, FEB 13, 2019, View Source [SID1234533295]). The panel titled, "Navigating FDA Approvals for Cell Therapy" will focus on regulatory aspects of developing CAR-T and other cell therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition to Dr. Kumar, other participants on the panel will include executives from Atara Biotherapeutics, Inc., Intellia Therapeutics, Inc., and Iovance Biotherapeutics, Inc.

The Business of Biotech Conference is an annual event held by Moffitt Cancer Center that brings together investors and experts from academia and industry interested in learning about the most advanced technologies in cancer research. For those interested in attending, please review the agenda and register here: View Source

Dr. Kumar stated, "I am pleased to be attending and presenting at this conference. Moffitt Cancer Center is one of the top cancer centers in the world and a critical partner for Anixa. I am also pleased to be participating with colleagues from other leading CAR-T and cell therapy companies."